Subscribe
Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.
Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH
Charles C. Wykoff MD, PhD; Diana V. Do, MD; Dante Pieramici, MD, FASRS; Jed H. Assam, MD, MS
John Kitchens, MD; Michael W. Stewart, MD
Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
Murtaza K. Adam, MD, FASRS; Deepak Sambhara, MD, FASRS; Betty Zhang, OD